Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights
MZEMZE782 Phase 1 Trial in Healthy Volunteers to Provide Proof of Mechanism Data for Phenylketonuria (PKU) and Chronic Kidney Disease (CKD) Expected in Q3 2025
August 12, 2025Earnings
Read more →